Tumor Treating Fields<br><span> research grants</span>

Tumor Treating Fields
research grants

Novocure and the American Association for Cancer Research are accepting applications for Tumor Treating Fields research grants and career development awards totaling more than $2 million.

learn more
lung cancer<br><span>trial update</span>

lung cancer
trial update

The final patient has been enrolled in our phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields together with immune checkpoint inhibitors or docetaxel for treatment of patients with advanced stage 4, non-small cell lung cancer following progression while on or after platinum-based therapy.

learn more
new phase 2<br><span> trial results</span>

new phase 2
trial results

University of Florida neuro-oncologist Dr. David Tran released updated data from the phase 2 pilot 2-THE-TOP trial testing the safety and efficacy of Tumor Treating Fields together with pembrolizumab and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma.

learn more
ovarian cancer <br><span>trial update</span>

ovarian cancer
trial update

The final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the safety and efficacy of Tumor Treating Fields together with paclitaxel for treatment in patients with platinum-resistant ovarian cancer.

learn more
Q3 financial <br><span>results </span>

Q3 financial
results

We reported third quarter financial results for 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth of the company.

learn more

the story
of Novocure

We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia. With more than 20 years of research and many significant milestones, we believe we are only beginning.

Learn More

we can leverage physics to fight cancer

Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division.

OUR THERAPY

explore our clinical pipeline

Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.

OUR PIPELINE

we are dedicated to making a difference in cancer

Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.

PATIENT-FORWARD